Skip to main content
S.Biomedics Co., Ltd. logo

S.Biomedics Co., Ltd. — Investor Relations & Filings

Ticker · 304360 ISIN · KR7304360001 KO Professional, scientific and technical activities
Open in API
Filings indexed 138 across all filing types
Latest filing 2023-03-03 Capital/Financing Update
Country KR South Korea
Listing KO 304360

About S.Biomedics Co., Ltd.

https://www.sbiomedics.com/eng/

S.Biomedics Co., Ltd. is a company specializing in the research and development of cell therapies for regenerative medicine. Established in 2005, the company focuses on creating, manufacturing, and supplying stem cell-based therapeutic products. Its core activities involve leveraging data-driven biology to develop fundamental and safe treatments for various conditions, with a significant focus on neurodegenerative disorders such as Parkinson's disease. S.Biomedics is committed to advancing the field of stem cell therapy from initial research to clinical application.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by S-Biomedics. It details corrections and additions to the original registration statement, specifically focusing on risk factors, business operations, and pipeline information. In the context of financial filings, a Securities Registration Statement (and its amendments) is a regulatory filing required for public offerings or listings, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific categories like 10-K, IR, or ER.
2023-03-03 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details the company's (S-Biomedics) intent to offer shares, including information on the offering, investment risks, and business overview. This is a formal regulatory filing required for public offerings and does not fit into the other specific categories like 10-K or Earnings Release. Therefore, it is classified as a Regulatory Filing.
2023-02-13 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for S.Biomedics Co., Ltd., covering the period from January 1, 2022, to September 30, 2022. It contains detailed company information, management history, capital changes, and business descriptions, which are characteristic of a comprehensive interim financial report. It is not a short announcement or a certification, but the full report itself. 9M 2022
2022-11-14 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'S.Biomedics Co., Ltd.' covering the period from January 1, 2022, to June 30, 2022. It contains detailed company information, management history, capital changes, and business descriptions, which are characteristic of a formal interim financial report filed with the Financial Supervisory Service (FSS) in South Korea. According to the provided definitions, this falls under the 'Interim / Quarterly Report' (IR) category. H1 2022
2022-08-12 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for S.Biomedics Co., Ltd. covering the period from January 1, 2022, to March 31, 2022. It contains detailed company information, management history, capital structure, and business descriptions, which are characteristic of a comprehensive interim financial report. It is not a mere announcement or certification, as it provides substantive financial and operational data. Q1 2022
2022-05-13 Korean
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for S-Biomedics Co., Ltd. for the fiscal year ending December 31, 2021. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This document constitutes the full annual financial reporting package, which falls under the 'Annual Report' (10-K) category in the provided schema, as it contains the substantive financial data and audit results for the full fiscal year. FY 2021
2022-03-31 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.